Granules India Ltd
Granules India Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
2 of 3 strong
The short version
Granules India expects continued strong growth in FY27, building on a 22% YoY growth in Q1 FY27 and similar growth trajectory in prior quarters. Granules India anticipates continued strong revenue growth, with 22% YoY growth in Q1 FY27 and similar growth trajectory expected for full FY27 (Page 6).
From Granules India Ltd's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Granules India expects continued strong growth in FY27, building on a 22% YoY growth in Q1 FY27 and similar growth trajectory in prior quarters.
- Complex generics, now 50% of finished dosages (up from 39% a year ago), are a key growth driver with sustainable growth expected.
- Europe is seen as a strong growth market with a positive upward trajectory due to increased demand for products filed in the past.
- Controlled substance products are growing, with existing products expanding market share and 1-2 new controlled substance launches expected starting FY28.
2 more points from Granules India Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Granules India Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex in Q1 FY27 was INR 89 crores; Genome Valley major investment completed.
- Total capex guidance for FY27 remains at INR 600 crores, with further investments in digitalization and modular growth projects.
- Oncology investment plan: around INR 100 crores for intermediates and INR 200 crores for API side, spread over multiple years.
- Expansion of peptide intermediate plant in India underway; equipment ordered to scale solid phase synthesis, purification columns, and lyophilization capacity.
- Genome Valley facility adds about 40% to formulation capacity; currently under scale-up.
2 more points from Granules India Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what Granules India Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Granules India Limited has about 23-24 ANDA filings still pending approval.
- Of these, 9 products are pending facility approval.
- Approximately 9 products are pending approvals, primarily due to IP-related issues.
- An additional 5 products from the U.S. are still pending approval; some are IP-based while others await regulatory approval.
- In the oncology segment, 2 ANDAs have been filed in the U.S. and Europe, with around 14 extensions of the same dossiers in various countries.
- The company has 9 to 13 oncology products at various stages of development.
2 more points from Granules India Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Granules India Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.5K Cr, net profit ₹202 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Granules India Ltd's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q1 FY26 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Trident Lifeline Ltd (Q1 FY27)
Q1 FY26: ₹23.6 crores . Key investor presentation takeaways from Trident Lifeline Ltd's Q1 FY27 investor presentation — and how it ranks against sector peers.
- Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
- Wanbury Ltd (Q1 FY27)
Q4FY26 Revenue from Operations: ₹164.58 Crore . Key concall takeaways from Wanbury Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.
- Symbiotec Pharma (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹218.2 crores, up 7% YoY from ₹203.2 crores in Q1 FY26 (Page 9). Key concall takeaways from Symbiotec Pharmalab…
Arthneeti Pro · Annual
Granules India Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Granules India Ltd Q1 FY27 results?
Granules India expects continued strong growth in FY27, building on a 22% YoY growth in Q1 FY27 and similar growth trajectory in prior quarters. Granules India anticipates continued strong revenue growth, with 22% YoY growth in Q1 FY27 and similar growth trajectory expected for full FY27 (Page 6).
What is Granules India Ltd share price analysis?
Granules India Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 34.6 with a market cap of ₹22,514 Cr. Investors should review the full earnings analysis for detailed insights.
Is Granules India Ltd planning capital expenditure?
Capex in Q1 FY27 was INR 89 crores; Genome Valley major investment completed.
Keep Granules India Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.